Olema Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Olema Oncology (NASDAQ:OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in five major investor conferences in September 2025.

The company will present at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 8), and H.C. Wainwright Global Investment Conference (Sept 9). All conferences will take place in Boston and New York, featuring a mix of presentations and fireside chats.

Investors can access live webcasts and recordings through Olema's investor relations website at ir.olema.com.

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

Citi’s 2025 Biopharma Back to School Conference
Date and Time: September 2, 2025 at 4 p.m. ET
Format: Fireside Chat
Location: Boston, MA

Wells Fargo 2025 Healthcare Conference
Date and Time: September 3, 2025 at 3:45 p.m. ET
Format: Presentation
Location: Boston, MA

Cantor Global Healthcare Conference 2025
Date and Time: September 4, 2025 at 11:30 a.m. ET
Format: Fireside Chat
Location: New York, NY

Morgan Stanley 23^rd Annual Global Healthcare Conference
Date and Time: September 8, 2025 at 10 a.m. ET
Format: Fireside Chat
Location: New York, NY

H.C. Wainwright 27^th Annual Global Investment Conference
Date and Time: September 9, 2025 at 9:30 a.m. ET
Format: Fireside Chat
Location: New York, NY

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

When and where is Olema Oncology (OLMA) presenting at investor conferences in September 2025?

Olema will present at five conferences: Citi's Biopharma (Sept 2, Boston), Wells Fargo (Sept 3, Boston), Cantor Global (Sept 4, NYC), Morgan Stanley (Sept 8, NYC), and H.C. Wainwright (Sept 9, NYC).

How can investors access Olema Oncology's (OLMA) conference presentations?

Investors can access live webcasts and recordings of the presentations through Olema's investor relations website at ir.olema.com, subject to event host permissions.

What type of company is Olema Oncology (OLMA)?

Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and beyond.

What is the format of Olema Oncology's (OLMA) conference presentations?

The presentations include a mix of formats: fireside chats at Citi's, Cantor, Morgan Stanley, and H.C. Wainwright conferences, and a presentation at the Wells Fargo conference.